CD79A and cranioectodermal dysplasia: NICE and BSG recommend against a nonbiopsy approach for the following reasons: Not all IgA TTG testing kits are reliable, and there is a high potential for false negatives and reduced test sensitivity because 2% of patients with CeD are IgA deficient (19, 20).